Walleye Capital’s OptimizeRx OPRX Stock Holding History

Walleye Capital’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,500	Closed	-$304K	–	4950
2025 Q2	$304K	Buy	+22,500	New	+$246K	﹤0.01%	3044
2023 Q4	–	Sell	-200	Closed	-$1.56K	–	5359
2023 Q3	$1.56K	Buy	+200	New	+$2.18K	﹤0.01%	4735
2023 Q2	–	Sell	-1,800	Closed	-$26.3K	–	4737
2023 Q1	$26.3K	Buy	+1,800	New	+$30.1K	﹤0.01%	3344

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Walleye Capital's OPRX Position: Q3 2025 in Review

Walleye Capital sold out of OptimizeRx (OPRX) in Q3 2025, closing a stake of 25,108 shares — an estimated $339K sold.

Walleye Capital first reported a position in OPRX in Q3 2021 and held it in 9 quarters. The position peaked at $1.35M in Q3 2022. 125 funds tracked by Wall St. Rank hold OPRX as of Q3 2025.

Walleye Capital reported no remaining OptimizeRx position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 25,108 OptimizeRx shares in Q3 2025, an estimated $339K.
Walleye Capital first reported a position in OptimizeRx in Q3 2021 and held it in 9 quarters.
Walleye Capital's OptimizeRx position peaked at $1.35M in Q3 2022.
125 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.